Saturday, November 28, 2009

FDA OKs Novartis Vaccine Against Seasonal Flu In Fast Review - Wall Street Journal


FDA OKs Novartis Vaccine Against Seasonal Flu In Fast Review
Wall Street Journal
Novartis's shares slid 0.9% to $54.90 in after-hours trading. The stock has gained nearly one-quarter in the past year.

and more »

FDA OKs Novartis Vaccine Against Seasonal Flu In Fast Review - Wall Street Journal


FDA OKs Novartis Vaccine Against Seasonal Flu In Fast Review
Wall Street Journal
Novartis's shares slid 0.9% to $54.90 in after-hours trading. The stock has gained nearly one-quarter in the past year.

and more »

FDA OKs Novartis Vaccine Against Seasonal Flu In Fast Review - Wall Street Journal


FDA OKs Novartis Vaccine Against Seasonal Flu In Fast Review
Wall Street Journal
Novartis's shares slid 0.9% to $54.90 in after-hours trading. The stock has gained nearly one-quarter in the past year.

and more »

FDA OKs Novartis Vaccine Against Seasonal Flu In Fast Review - Wall Street Journal


FDA OKs Novartis Vaccine Against Seasonal Flu In Fast Review
Wall Street Journal
Novartis's shares slid 0.9% to $54.90 in after-hours trading. The stock has gained nearly one-quarter in the past year.

and more »

FDA OKs Novartis Vaccine Against Seasonal Flu In Fast Review - Wall Street Journal


FDA OKs Novartis Vaccine Against Seasonal Flu In Fast Review
Wall Street Journal
Novartis's shares slid 0.9% to $54.90 in after-hours trading. The stock has gained nearly one-quarter in the past year.

and more »

FDA OKs Novartis Vaccine Against Seasonal Flu In Fast Review - Wall Street Journal


FDA OKs Novartis Vaccine Against Seasonal Flu In Fast Review
Wall Street Journal
Novartis's shares slid 0.9% to $54.90 in after-hours trading. The stock has gained nearly one-quarter in the past year.

and more »

FDA OKs Novartis Vaccine Against Seasonal Flu In Fast Review - Wall Street Journal


FDA OKs Novartis Vaccine Against Seasonal Flu In Fast Review
Wall Street Journal
Novartis's shares slid 0.9% to $54.90 in after-hours trading. The stock has gained nearly one-quarter in the past year.

and more »